Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04016818
Recruitment Status : Not yet recruiting
First Posted : July 12, 2019
Last Update Posted : July 12, 2019
Sponsor:
Information provided by (Responsible Party):
Stanford University

Brief Summary:
This is a research study of a novel, "breast-dedicated" positron emission tomography (PET) camera with 1 millimeter spatial resolution. The main goal of the study is for the personnel to understand practical and logistical issues with using the camera in the clinic

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: 18F-FDG Device: Breast-dedicated PET camera Early Phase 1

Detailed Description:

Primary Objective To obtain initial experience using the novel, breast-dedicated PET camera design in the breast imaging clinic.

Secondary Objectives To understand, given the 10-fold higher sensitivity of this novel camera, how low we can go with administered tracer dose, and, given the >100-fold better volumetric spatial resolution, understand the achievable image quality.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: Pilot Study of a Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution
Estimated Study Start Date : December 2019
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 18-F FDG Study using Breast-Dedicated PET Camera
Breast-Dedicated PET Camera will be used with standard PET 18-F FDG tracer dose
Drug: 18F-FDG
Participant will be injected IV (intravenously) with 10 ± 2 mCi of 18F-FDG.
Other Names:
  • 18F-fluorodeoxiglucose
  • 18F-FDG radiotracer

Device: Breast-dedicated PET camera
Breast-dedicated PET camera designed by Stanford satellite radiochemistry facility




Primary Outcome Measures :
  1. Image quality with the breast-dedicated PET camera [ Time Frame: 1 day ]
    Feasibility of the pilot breast-dedicated PET camera will be assessed on the basis of whether acceptable images are obtained. Images will be assessed and graded as 1 of 3 quality ratings: excellent, good, and poor. The outcome will be reported as the number of images that are excellent, good, and poor, a number without dispersion.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Biopsy-confirmed breast cancer measuring ≥ 5 mm on mammogram or ultrasound.
  • Prior diagnostic imaging test(s) with another modality such as MRI, CT, or x-ray mammography (or other applicable imaging modalities) within 60 days prior to the study date.
  • Documented written informed consent document.

Exclusion Criteria:

  • 1. Additional condition, or extenuating circumstance that, in the opinion of the investigator, may interfere with study compliance.
  • Known allergies to FDG
  • Pregnant or nursing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04016818


Contacts
Layout table for location contacts
Contact: Risa Jiron 650-736-1598 rjiron@stanford.edu

Locations
Layout table for location information
United States, California
Stanford University Not yet recruiting
Stanford, California, United States, 94304
Contact: Risa Jiron    650-736-1598    rjiron@stanford.edu   
Sponsors and Collaborators
Stanford University
Investigators
Layout table for investigator information
Principal Investigator: Wendy B DeMartini Stanford University

Layout table for additonal information
Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT04016818     History of Changes
Other Study ID Numbers: IRB-50877
BRS0102 ( Other Identifier: OnCore )
IRB-50877 ( Other Identifier: Stanford IRB )
First Posted: July 12, 2019    Key Record Dates
Last Update Posted: July 12, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Fluorodeoxyglucose F18
Radiopharmaceuticals
Molecular Mechanisms of Pharmacological Action